Results 91 to 100 of about 18,035 (133)

Consensus H3N2 HA immunogens incorporating key antigenic mutations elicit broad-spectrum neutralizing responses. [PDF]

Emerg Microbes Infect
An Y, Cai M, Zhao C, Zhang M, Wu X, Huang W, Zhou X, Wang Y.   +7 more
europepmc   +1 more source

Evaluation of Immunogenicity and Cross-Protective Efficacy of a CpG-Adjuvanted Trivalent Inactivated Influenza Vaccine in Ferrets. [PDF]

Vaccines (Basel)
Qiu Y, Zhang Y, He S, Wang Y, Wang R, Han Y, He W, Sho E, Han S, Wu H.   +9 more
europepmc   +1 more source

Surveillance and biological characterization of H3 subtype avian influenza viruses in Eastern China. [PDF]

Virulence
Miao X, Zhao X, Zhang N, Yin Y, Xu X, Wang J, Chen S, Wu H, Peng D, Qin T, Liu X.   +10 more
europepmc   +1 more source

Influenza A/H3N2 epidemiology in England during the 2025 to 2026 season: a mathematical modelling study. [PDF]

Commun Health
Hay JA, Alahakoon P, Greenshields-Watson A, Kendall M, Ghafari M, Wymant C, Hinch R, Ferretti L, Panovska-Griffiths J, Fraser C.   +9 more
europepmc   +1 more source

Molecular Surveillance and Genomic Characterization of Influenza A(H3N2) Viruses From a Secondary-Care Surveillance Site in Pakistan During the 2025-2026 Winter Season. [PDF]

J Med Virol
Javed A, Hayat J, Haider SA, Jamal Z, Hakim R, Ali Q, Bullo MMH, Tahir M, Salman M, Javed Y, Waheed Y, Umair M.   +11 more
europepmc   +1 more source

Influenza vaccine effectiveness against outpatient acute respiratory illness with laboratory-confirmed influenza, United States, 2024-25 season. [PDF]

Clin Infect Dis
Chung JR, Price AM, House SL, Mills J, Wernli KJ, Sanchez M, Martin ET, Vaughn IA, Murugan V, Kramer J, Saade EA, Faryar K, Gaglani M, Raiyani C, Zimmerman RK, Taylor LH, Williams OL, Walter EB, DaSilva J, Kirby MK, Levine MZ, Kondor R, Noble EK, Sumner KM, Ellington SR, Flannery B, US Flu VE Network Investigators.   +26 more
europepmc   +1 more source

Adaptive Advantage of the Emerging Seasonal Influenza A (H3N2) Subclade K: Enhanced Receptor Binding Capacity and Immune Escape Potential. [PDF]

MedComm (2020)
Zhang L, Zhao T, Pan X, Feng Z, Zhang D, Wang Q, Yang P.   +6 more
europepmc   +1 more source

Influenza Virus Isolation for Public Health Surveillance Before, During, and After the COVID-19 Pandemic: Experiences from the New York State National Influenza Reference Center Laboratory. [PDF]

Infect Dis Rep
Moghe AP, Leak ES, Laplante JM, St George K.   +3 more
europepmc   +1 more source

A Sequence-Based Update on Amino Acid Substitutions in Influenza Polymerase Acidic Protein in Europe That Alter Baloxavir Susceptibility From 2009 to 2025. [PDF]

Influenza Other Respir Viruses
Martín-Toribio A, Inchausti-Moya I, Toquero-Asensio M, García-Díaz S, Sanchez-Martinez J, Rodriguez-Crespo C, Galindo-Carretero S, Iglesia-Aparicio R, Lopez-Gonzalo C, Antón-Contreras A, Rojo-Rello S, Dominguez-Gil M, Hernández M, Eiros JM, Nistal-Villan E, Sanz-Muñoz I.   +15 more
europepmc   +1 more source

ShinyVar: a web-based application for comparative Influenza variant analysis supporting structure-guided approaches to vaccine and antiviral drug design. [PDF]

PeerJ
Lee D, Sangket U.
europepmc   +1 more source